Advertisement

The NF-κB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas

Urban Novak, Andrea Rinaldi, Ivo Kwee, Subhadra V. Nandula, Paola M. V. Rancoita, Mara Compagno, Michaela Cerri, Davide Rossi, Vundavalli V. Murty, Emanuele Zucca, Gianluca Gaidano, Riccardo Dalla-Favera, Laura Pasqualucci, Govind Bhagat and Francesco Bertoni

Article Information

Citation 
vol. 113 no. 20 4918-4921
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted August 12, 2008
  • Accepted January 22, 2009
  • Published online May 14, 2009.

Article Versions


Contributors 
  • Urban Novak, 1Institute for Cancer Genetics, Departments of Pathology and Genetics & Development, and the Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY;
  • Andrea Rinaldi, 2Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland;
  • Ivo Kwee, 2Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland; 3Istituto Dalle Molle di Studi sull'Intelligenza Artificiale, Manno, Switzerland; and
  • Subhadra V. Nandula, 1Institute for Cancer Genetics, Departments of Pathology and Genetics & Development, and the Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY;
  • Paola M. V. Rancoita, 2Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland; 3Istituto Dalle Molle di Studi sull'Intelligenza Artificiale, Manno, Switzerland; and
  • Mara Compagno, 1Institute for Cancer Genetics, Departments of Pathology and Genetics & Development, and the Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY;
  • Michaela Cerri, 4Division of Hematology, Department of Clinical and Experimental Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
  • Davide Rossi, 4Division of Hematology, Department of Clinical and Experimental Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
  • Vundavalli V. Murty, 1Institute for Cancer Genetics, Departments of Pathology and Genetics & Development, and the Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY;
  • Emanuele Zucca, 2Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland;
  • Gianluca Gaidano, 4Division of Hematology, Department of Clinical and Experimental Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
  • Riccardo Dalla-Favera, 1Institute for Cancer Genetics, Departments of Pathology and Genetics & Development, and the Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY;
  • Laura Pasqualucci, 1Institute for Cancer Genetics, Departments of Pathology and Genetics & Development, and the Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY;
  • Govind Bhagat, 1Institute for Cancer Genetics, Departments of Pathology and Genetics & Development, and the Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY;
  • Francesco Bertoni, 2Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output